Yield10 Bioscience Inc
NASDAQ:YTEN
Yield10 Bioscience Inc
NASDAQ:YTEN
Price:
0.239 USD
1.92%
Updated:
Apr 26, 2024
Section:
Relative Value
The Relative Value of one
YTEN
stock under the Base Case scenario is
14.374
USD.
Compared to the current market price of 0.239 USD,
Yield10 Bioscience Inc
is
Undervalued by 98%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
YTEN
Relative Value
Base Case
14.374
USD
Undervaluation 98%
Valuation Multiples
Multiples Across Competitors
YTEN Competitors Multiples
Yield10 Bioscience Inc Competitors
Yield10 Bioscience Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Yield10 Bioscience Inc
NASDAQ:YTEN
|
3.7m USD | 61.4 | -0.3 | -0.2 | -0.2 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
286.7B USD | 5.3 | 59.5 | 12.9 | 19.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
144.8B USD | 5.1 | 21.6 | 16.1 | 24.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102.5B USD | 10.4 | 28.3 | 22.6 | 23.7 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
96.9B USD | 7.4 | 24.5 | 16.2 | 17.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
132B AUD | 6.1 | 34.9 | 21.1 | 26.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 14.4 | 7.9 | 10.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
41.2B USD | 6 | -8.7 | -9.2 | -7.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
29.9B USD | 3 | 25.8 | 14 | 17.4 | |
| KR |
|
Celltrion Inc
KRX:068270
|
36.6T KRW | 16.8 | 68.3 | 41.9 | 57.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
